Sartorius Stedim Biotech (SDMHF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Sartorius and Sartorius Stadium Biotech H1 2025 conference call and live webcast. I am Mathilde, the chorus call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. This call is scheduled for 60 minutes. The presentation will be followed by a Q&A session. In order to give all participants the opportunity to ask a question, we ask that the number of questions per person be limited to two. In addition, and in the interest of all participants, questions with the same content will only be answered once. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Michael Grothirk, CEO. Please go ahead. Thank you, Mathilde, and good afternoon, everyone, and thank you for joining today's call on our H1 results of the Sartorius AG, as well as Sartorius Data and Biotech. Today, I'm together with Florian Funk, our CFO with René Faber, our Head of Bioprocessing Division and CEO of Sartorius Data and Biotech, and also Alexandra Gatzemeier, our head of the lab division. But before I walk you through our financials and the full year outlook of the Sartorius AG, I would like to take the opportunity to introduce myself and share how excited I am to step into the role of the CEO at Sartorius. Maybe very briefly on my vita, you may have seen that I hold a degree in mechanical engineering and a PhD and spent the last 20 years in the processing and packaging industry for pharmaceuticals and for food. Most recently as CEO of Syntagon, a spin-off of Bosch. And before that, I spent many years...